Collectively, these findings suggest that RCC1 overexpression may lead to chemoresistance by accelerating cell cycle progression and DNA repair, highlighting its potential as a compelling therapeutic target for overcoming chemoresistance in cancer therapy. Here, RCC1 is linked to cancer.